Clinical Trials | December 04, 2025
Jacobio combo delivers 71% ORR, sets stage for first SHP-2–based NSCLC therapy
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
O'Connor brings over 30 years of leadership experience in the biotechnology and oncology sectors
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
The acquisitions merge DatCard and Sorna’s expertise in clinical data sharing with Avandra’s de-identified patient data aggregation platform
The platform integrates with CT imaging and uses deep learning models to generate a 3D digital twin of lung anatomy
Armlupeg is indicated for decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs
StarGuide GX delivers ultra-high sensitivity and high-resolution imaging, enabling fast, confident diagnostics
Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders
The hospital has already onboarded 200+ experienced doctors and is expected to generate 5,000–7,000 jobs
Subscribe To Our Newsletter & Stay Updated
